retatrutide triple agonist gip glp-1 glucagon Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA TrimRX | GLP-1 vs GIP:

Rather than filing a handful of secondary patents, a company files dozens or hundreds, covering every conceivable aspect of the drug: its formulation, its manufacturing process, its dosing device, its method of administration, specific patient subpopulations

: #ECEC

Take the first step towards a balanced and healthier life today

Consequently, Schulzs groundbreaking observations of a biphasic, stimulatory-inhibitory response were largely dismissed by his contemporaries as experimental anomalies, delaying the formal recognition of hormesis for decades

Source Data Extended Data Fig./Table 1 (download XLSX Statistical source data

This is not a story about only nicotine or alcohol or heroin or cocaine or opiates, he says